{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.199","value":"0.31"},{"groupId":"OG001","spread":"18.190","value":"1.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"296"},{"groupId":"OG001","value":"144"}],"units":"Participants"}],"title":"C2D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.175","value":"0.96"},{"groupId":"OG001","spread":"17.098","value":"2.80"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"277"},{"groupId":"OG001","value":"134"}],"units":"Participants"}],"title":"C3D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.293","value":"1.92"},{"groupId":"OG001","spread":"18.592","value":"4.09"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"265"},{"groupId":"OG001","value":"114"}],"units":"Participants"}],"title":"C4D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.912","value":"3.35"},{"groupId":"OG001","spread":"21.686","value":"2.28"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"254"},{"groupId":"OG001","value":"106"}],"units":"Participants"}],"title":"C5D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.649","value":"3.42"},{"groupId":"OG001","spread":"19.452","value":"2.89"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"101"}],"units":"Participants"}],"title":"C6D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.657","value":"3.65"},{"groupId":"OG001","spread":"21.236","value":"2.02"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"203"},{"groupId":"OG001","value":"66"}],"units":"Participants"}],"title":"C9D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.056","value":"2.37"},{"groupId":"OG001","spread":"23.862","value":"3.54"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"title":"C12D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.090","value":"6.23"},{"groupId":"OG001","spread":"22.091","value":"6.61"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"29"}],"units":"Participants"}],"title":"C15D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.578","value":"5.28"},{"groupId":"OG001","spread":"22.323","value":"10.09"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"120"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"title":"C18D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.340","value":"6.07"},{"groupId":"OG001","spread":"22.088","value":"18.59"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"title":"C21D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.347","value":"5.05"},{"groupId":"OG001","spread":"25.474","value":"10.83"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"title":"C24D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.905","value":"5.27"},{"groupId":"OG001","spread":"27.003","value":"8.33"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"C27D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.947","value":"6.82"},{"groupId":"OG001","spread":"45.896","value":"4.17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"C30D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.518","value":"4.56"},{"groupId":"OG001","spread":"25.459","value":"27.78"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"C33D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.363","value":"6.94"},{"groupId":"OG001","spread":"11.785","value":"41.67"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"C36D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.826","value":"-2.70"},{"groupId":"OG001","spread":"23.422","value":"-0.99"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"59"}],"units":"Participants"}],"title":"Follow-up 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"297"},{"groupId":"OG001","value":"144"}],"units":"Participants"}],"description":"The EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall QoL in cancer participants. It consists of 15 domains: 1 Global Health Status (GHS)/QoL scale, 5 functional scales (Physical, role, cognitive, emotional, social), 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact). Reported here are the EORTC QLQ-C30 GHS/QoL scores only. GHS/QoL is derived from two items-\"How would you rate your overall health during the past week?\" and \"How would you rate your overall quality of life during the past week?\"-each scored from 1 (very poor) to 7 (excellent). The average of these two items is linearly transformed to a 0-100 scale; higher scores indicate better overall quality of life, and a positive change from baseline reflects improvement.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received cemiplimab plus platinum-based doublet chemotherapy","id":"OG000","title":"Part 2: Cemiplimab + Chemotherapy"},{"description":"Placebo matching cemiplimab plus platinum-based doublet chemotherapy","id":"OG001","title":"Part 2: Placebo + Chemotherapy"}],"paramType":"MEAN","populationDescription":"Includes only participants in part 2 with both baseline and at least one post-baseline value. Overall number of participants analysed = participants evaluable for the outcome measure. Number analyzed = participants evaluable at the specified timepoint","reportingStatus":"POSTED","timeFrame":"Baseline, Day 1 of 21-Day Cycles 2, 3, 4, 5, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36; Follow-up 1 (14 to 30 days after last study treatment)","title":"Part 2: Change From Baseline in Global Health Status Score as Measured by the EORTC QLQ-C30","type":"SECONDARY","unitOfMeasure":"Score on a Scale"}